ERBB2 and cancer: Currently, the main international guidelines on DIILD are not specific to cancer therapy, mainly address immunotherapy-related adverse effects and often provide inconsistent management recommendations.6, 7, 8 Very recently, a review article focused on the current knowledge of the pathogenesis and epidemiologic characteristics of anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)-related lung toxicity, proposing strategies for its diagnosis and treatment.9